Orion Corporation, Orion Pharma (primary packaging, secondary packaging, batch release; bulk manufacturing; bulk manufacturing, quality control (excluding microbiological purity testing), quality control (microbiological purity testing))

The drug is indicated for the treatment of adult men with high-risk metastatic non-metastatic castration-resistant prostate cancer, as well as metastatic hormone-sensitive prostate cancer (in combination with docetaxel and androgen deprivation therapy).

Dosage form: tablets, film-coated

ATC: L02BB06